Current Clinical Treatments and Challenges for Heart Failure and Cardiogenic Shock
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".
Deadline for manuscript submissions: closed (20 October 2025) | Viewed by 1089
Special Issue Editors
Interests: cardiogenic shock; mechanical circulatory support; ventricular assist devices; right ventricular dysfunction; veno-arterial ECMO; veno-venous ECMO; cardiac anesthesia; ARDS
Special Issues, Collections and Topics in MDPI journals
2. Centro Cuore GB Morgagni, 95125 Catania, Italy
Interests: cardiogenic shock; advanced heart failure; mechanical circulatory support; ventricular assist devices; biocompatibility; right ventricular dysfunction; veno-arterial ECMO; veno-venous ECMO; ARDS
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Background: Heart failure and cardiogenic shock continue to be associated with significant morbidity and mortality, with a wide spectrum of etiologies and each patient presenting with peculiar characteristics. While current therapies for chronic heart failure are numerous and supported by strong and growing bodies of evidence, the best treatment strategy for patiens suffering from cardiogenic shock remains to be defined. Importantly, the intersection between the acute phase and the opportunity to start guideline-directed medical therapy has not yet been reported. Inotropes are often use in clinical practice, but no impact on outcomes has been demonstrated. Moreover, their cardiocirculatory effects, when prolonged, may be deleterious. By contrast, early MCS may reduce the need of inotropes/vasopressors; however, the best available evidence on the medical treatment of heart failure is not acknowledged in cardiogenic shock. MCS use has risen dramatically, with Impella CP having recently been shown to be superior to standard therapy, but catecholamine use is still very widespread. Goals: The aim of this work is to focus on contemporary drug management in the clinical scenario of cardiogenic shock, acknowledging the evidence from RCTs and leveraging that on GDMT to further improve the outcomes of patients with severe heart failure. We also aim to provide information on the potential for native heart recovery and its associated benefits, as well as discuss the new frontiers of heart replacement with a totally artificial heart and its role in very sick patients.
Information to Authors: Led by an interdisciplinary team of experts, this Special Issue is open for submissions of original articles, reviews, and viewpoints focused on MCS and cardiogenic shock, with a specific focus on patients with heart failure. The areas of interest include but are not limited to the following: (1) hemodynamic adaptations after MCS; (2) identification of biventricular failure; (3) PCI strategies in MCS-supported patients with CS; and (4) perioperative optimization of high-risk patient candidates for heart replacement therapies.
Dr. Andrea Montisci
Prof. Dr. Federico Pappalardo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cardiogenic shock
- heart failure
- mechanical circulatory support
- Impella
- veno-arterial ECMO
- unloading
- heart failure
- heart transplant
- artificial heart
- left ventricular assist devices
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
